Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval ...
Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...